Connection

Frederick Hayden to Betacoronavirus

Back to Details
This is a "connection" page, showing publications Frederick Hayden has written about Betacoronavirus.
Frederick Hayden
Connection Strength
0.035
Betacoronavirus
  1. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020 Oct; 14(5):601-612.
    View in: PubMed
    Score: 0.009
  2. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020 May 24; 21(1):422.
    View in: PubMed
    Score: 0.009
  3. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 05 07; 382(19):1787-1799.
    View in: PubMed
    Score: 0.009
  4. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020 06; 48(6):e440-e469.
    View in: PubMed
    Score: 0.002
  5. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 05 16; 395(10236):1569-1578.
    View in: PubMed
    Score: 0.002
  6. A novel coronavirus outbreak of global health concern. Lancet. 2020 02 15; 395(10223):470-473.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.